233 related articles for article (PubMed ID: 32096310)
1. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
[TBL] [Abstract][Full Text] [Related]
2. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
Knop V; Hoppe D; Welzel T; Vermehren J; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Zeuzem S; Welker MW
J Viral Hepat; 2016 Dec; 23(12):994-1002. PubMed ID: 27500382
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
[TBL] [Abstract][Full Text] [Related]
4. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
5. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
6. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
7. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
8. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
9. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment.
Sirinawasatien A; Supawan P
Medicine (Baltimore); 2024 May; 103(19):e38096. PubMed ID: 38728473
[TBL] [Abstract][Full Text] [Related]
11. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
Knop V; Hofmann WP; Buggisch P; Klinker H; Mauss S; Günther R; Hinrichsen H; Hüppe D; Pfeiffer-Vornkahl H; Simon KG; Berg T; Manns MP; Friedrich-Rust M;
J Viral Hepat; 2019 Feb; 26(2):224-230. PubMed ID: 30315694
[TBL] [Abstract][Full Text] [Related]
12. Significant decrease in liver stiffness detected by two dimensional shear-wave elastography after treatment with direct-acting antiviral agents in patients with chronic Hepatitis C.
Yaraş S; Sezgin O; Üçbilek E; Özdoğan O; Altıntaş E
Turk J Gastroenterol; 2020 Feb; 31(2):142-147. PubMed ID: 32141823
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment.
Sporea I; Lupușoru R; Mare R; Popescu A; Gheorghe L; Iacob S; Șirli R
J Gastrointestin Liver Dis; 2017 Jun; 26(2):145-150. PubMed ID: 28617884
[TBL] [Abstract][Full Text] [Related]
14. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
[TBL] [Abstract][Full Text] [Related]
15. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.
Kohla MAS; Fayoumi AE; Akl M; Abdelkareem M; Elsakhawy M; Waheed S; Abozeid M
Clin Exp Med; 2020 Feb; 20(1):143-148. PubMed ID: 31792631
[TBL] [Abstract][Full Text] [Related]
16. Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era.
Piecha F; Gänßler JM; Ozga AK; Wehmeyer MH; Kluwe J; Lampalzer S; Creutzfeldt AM; Buescher G; Horvatits T; Sterneck M; Pischke S; Lohse AW; Schulze Zur Wiesch J
Scand J Gastroenterol; 2021 Jul; 56(7):840-848. PubMed ID: 34010581
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
18. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
